{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:01:10Z","timestamp":1781614870091,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Timely initiation of therapy is critical for patients with HER2-positive early breast cancer, especially in low- and middle-income countries (LMICs) where health-system constraints delay care. We evaluated whether a Patient Navigation Program could reduce time from registration to initiation of dual anti-HER2 therapy in Egypt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective cohort study at the Breast Cancer Comprehensive Center (BCCC). Trained navigators tracked diagnostics, scheduled multidisciplinary tumor board (MDT), prepared\/submitted Ministry of Health (MOH) approval files, monitored approval, and booked the earliest infusion slot. The primary endpoint was time from registration to therapy start; secondary endpoints were prespecified intervals\u2014T1 (registration\u2192MDT), T2 (MDT\u2192MOH submission), T3 (MOH submission\u2192MOH approval), and T4 (MOH approval\u2192therapy start), time to surgery, and pathological complete response (pCR). The primary analysis compared symmetric six-month windows: July\u2013December 2022 (without navigation) vs. January\u2013June 2023 (with navigation). A sensitivity analysis included all eligible patients: May\u2013December 2022 vs. January\u2013December 2023. Two-sided\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 was significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the primary analysis, navigation significantly shortened MOH approval \u2192 therapy start (T4) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008), while T1\u2013T3 and total time showed non-significant differences (total:\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.127). pCR was similar (78\/115 [67.8%] vs. 81\/117 [69.2%],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.818). In the sensitivity analysis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009441), total time decreased from 146.2\u2009\u00b1\u200976.6 to 121.6\u2009\u00b1\u200950.4 days (\u201324.6 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), driven by a large improvement in T4 (32.4\u219220.8 days; \u2212\u200911.6 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) while pCR remained comparable, although not statistically significant (64.1% vs. 69.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In an LMIC tertiary center, a Patient Navigation Program significantly accelerated the post-approval step to treatment and, across the full year, shortened the overall time from registration to initiation of dual anti-HER2 therapy despite rising volumes. These system-level gains, support navigation as a scalable, equity-promoting strategy aligned with World Health Organization (WHO)Global Breast Cancer Initiative priorities; prospective multicenter evaluations incorporating patient-reported outcomes and cost-effectiveness are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-025-13606-8","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:25:54Z","timestamp":1762601154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Streamlining care through patient navigation: a retrospective cohort study of timely anti-HER2 therapy in early breast cancer in a low-middle income country"],"prefix":"10.1186","volume":"25","author":[{"given":"Emad","family":"Shash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Alaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Abou","family":"El-Kheir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Elhosary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"issue":"3","key":"13606_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"13606_CR2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.breast.2011.02.007","volume":"20","author":"JB Harford","year":"2011","unstructured":"Harford JB, Otero IV, Anderson BO, et al. Problem solving for breast health care delivery in low and middle resource countries: consensus statement from the breast health global initiative. Breast. 2011;20(Suppl 2):S20\u20139.","journal-title":"Breast"},{"issue":"1","key":"13606_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/heapol\/czaa093","volume":"36","author":"S Louart","year":"2021","unstructured":"Louart S, Bonnet E, Ridde V. Is patient navigation a solution to the problem of leaving no one behind? A scoping review of evidence from low-income countries. Health Policy Plan. 2021;36(1):101\u201316.","journal-title":"Health Policy Plan"},{"issue":"15 Suppl","key":"13606_CR4","first-page":"3539","volume":"117","author":"HP Freeman","year":"2011","unstructured":"Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 2011;117(15 Suppl):3539\u201345.","journal-title":"Cancer"},{"issue":"10","key":"13606_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.26719\/emhj.22.076","volume":"28","author":"Y Rostom","year":"2022","unstructured":"Rostom Y, Abdelmoneim SE, Shaker M, Mahmoud N. Presentation and management of female breast cancer in egypt: an implementation study in a public hospital cohort. East Mediterr Health J. 2022;28(10):725\u201332.","journal-title":"East Mediterr Health J"},{"issue":"1","key":"13606_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive breast cancer (NeoSphere trial): a randomised multicentre phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"key":"13606_CR7","unstructured":"Morsy A. Presidential Initiative for Women\u2019s Health provides breast cancer screening and advanced treatments free of charge (Press conference remarks). Daily News Egypt. 2022 Mar 28."},{"key":"13606_CR8","doi-asserted-by":"publisher","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","DOI":"10.1016\/S0140-6736(13)62422-8"},{"issue":"5","key":"13606_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s11912-024-01514-9","volume":"26","author":"M Chen","year":"2024","unstructured":"Chen M, Wu VS, Falk D, et al. Patient navigation in cancer treatment: A systematic review. Curr Oncol Rep. 2024;26(5):504\u201337.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"13606_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/1055-9965.EPI-12-0479","volume":"21","author":"HJ Hoffman","year":"2012","unstructured":"Hoffman HJ, LaVerda NL, Young HA, et al. Patient navigation significantly reduces delays in breast cancer diagnosis in the district of Columbia. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1655\u201363.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"13606_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1200\/JOP.19.00230","volume":"15","author":"RM Kline","year":"2019","unstructured":"Kline RM, Rocque GB, Rohan EA, et al. Patient navigation in cancer: the business case to support clinical needs. J Oncol Pract. 2019;15(11):585\u201390.","journal-title":"J Oncol Pract"},{"key":"13606_CR12","doi-asserted-by":"publisher","first-page":"e20200068","DOI":"10.29289\/2594539420200068","volume":"31","author":"S Gioia","year":"2021","unstructured":"Gioia S, Brigag\u00e3o L, Rocha M, Goss P. Patient navigation: fighting for the rights of breast cancer patients in Brazil. Mastology. 2021;31:e20200068.","journal-title":"Mastology"},{"key":"13606_CR13","doi-asserted-by":"publisher","first-page":"e2300297","DOI":"10.1200\/GO.23.00297","volume":"10","author":"M Jaganathan","year":"2024","unstructured":"Jaganathan M, Ang BH, Ali A, et al. Presentation of breast cancer and impact of patient navigation on timeliness of diagnosis and treatment in a multicenter network in Malaysia. JCO Glob Oncol. 2024;10:e2300297.","journal-title":"JCO Glob Oncol"},{"key":"13606_CR14","volume-title":"The patient navigation project in Kigali, Rwanda \u2013 Case study report","author":"Rwanda Biomedical Centre (RBC) and City Cancer Challenge (C\/Can)","year":"2024","unstructured":"Rwanda Biomedical Centre (RBC) and City Cancer Challenge (C\/Can). The patient navigation project in Kigali, Rwanda \u2013 Case study report. Kigali: C\/Can; 2024."},{"key":"13606_CR15","volume-title":"Patient navigation for early detection, diagnosis and treatment of breast cancer: technical brief","author":"World Health Organization (WHO)","year":"2024","unstructured":"World Health Organization (WHO). Patient navigation for early detection, diagnosis and treatment of breast cancer: technical brief. Geneva: WHO; 2024."},{"issue":"1","key":"13606_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s13187-024-02472-3","volume":"40","author":"E Shash","year":"2025","unstructured":"Shash E, Bektash F, Elhosary M, Emam G, El-Sayed A, Abdelmenam D, et al. Enhancing patient outcomes through integrated education and navigation programs at the breast cancer comprehensive Center, National cancer Institute, Cairo university. J Cancer Educ. 2025;40(1):65\u201372. https:\/\/doi.org\/10.1007\/s13187-024-02472-3. Epub 2024 Jul 16. PMID:39012556.","journal-title":"J Cancer Educ"},{"issue":"5","key":"13606_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1470-2045(21)00071-1","volume":"22","author":"BO Anderson","year":"2021","unstructured":"Anderson BO, Ilbawi AM, El Saghir NS, et al. The global breast cancer initiative: A strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021;22(5):578\u201381.","journal-title":"Lancet Oncol"},{"key":"13606_CR18","doi-asserted-by":"publisher","unstructured":"Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016;2(6):751\u201360. https:\/\/doi.org\/10.1001\/jamaoncol.2015.6113","DOI":"10.1001\/jamaoncol.2015.6113"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13606-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:48:53Z","timestamp":1781614133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-025-13606-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13606"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13606-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of the National Cancer Institute, Cairo University (IRB Approval No. MO2407-305-033, dated 14\/07\/2024). The requirement for informed consent was waived for this retrospective analysis of de-identified data, in accordance with IRB guidelines and the Declaration of Helsinki. All patient data were kept confidential.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript contains no individual person\u2019s identifiable data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1454"}}